Concr Launches Trial Using Digital Twins for Outcome Prediction in Breast Cancer

Concr Launches Trial Using Digital Twins for Outcome Prediction in Breast Cancer

By, Admin 13 July 2024

Overview

Concr, a value-driven technology bio company, applying statistical learning and advanced modelling adopted from astrophysics to aid in precision treatment of cancer patients, announced that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining biomarkers of chemotherapy and immunotherapy response in early triple negative breast cancer (TNBC).

VISION Trial

  • VISION trial is an observational retrospective study focusing on women who were previously diagnosed with early TNBC and received chemotherapy followed by curative breast surgery. 
  • The 24-month-long study will collect historical clinical data and profile archival cancer biopsy samples from up to 200 women in order to identify and validate biomarkers of chemotherapy response, with and without immunotherapy.

Statement from VISION Project Lead

Triple negative breast cancer is an aggressive subtype of breast cancer. Hence, Concr has prioritised this clinical indication as a key research area by sponsoring the VISION study.  The VISION study will test the value created through the combination of clinical data, genomic data and machine learning approaches for enabling treatment stratification at an individual level. We believe this approach will represent the next generation of diagnostic platforms in cancer care” shared Dr Uzma Asghar, Concr’s chief scientific officer and VISION Project Lead.

AI-VISION for Multi-Centre Study 

  • The multi-centre study featuring UK and Australian sites backed by a prestigious Innovate UK Precision Medicine project grant (AI-VISION) was announced earlier this year, with key partners The Institute of Cancer Research, London, and The Institute for Computational Cosmology at Durham University. 
  • Patients will be recruited from The Royal Marsden NHS Foundation Trust, a globally-leading specialist cancer hospital, going live as the primary clinical site last month.

Statement from Principal Investigator

Dr Navita Somaiah, Principal Investigator and Clinician Scientist at The Institute of Cancer Research, London, and Clinical Oncologist at The Royal Marsden, said: “We’re very pleased to take the next step in this innovative project, which is using AI to try to uncover new methods to predict which women with triple negative breast cancer may respond better or less well to current therapies. We hope this collaboration will ultimately help to guide treatment for some women with this form of breast cancer”.

Concr’s FarrSight -Twin Technology

  • Concr’s FarrSight -Twin technology will utilise genomic data from diagnostic and surgical breast cancer samples together with whole-slide imaging and clinical data from trial participants to create a “digital twin” of every individual patient, which will be used to predict treatment response to chemotherapy (anthracycline, taxanes, platinum, anti-metabolites) and immunotherapy (pembrolizumab). 
  • Subsequently, FarrSight will be used to explore biological mechanisms behind sensitivity to chemotherapy +/- immunotherapy. 
  • This approach could pave a way to better stratify and treat TNBC, which disproportionately affects black women, while simultaneously testing a novel approach that could be readily deployed in clinic.

Words from CEO: Concr

While much of the dialogue surrounding AI in healthcare focuses on its potential, we must not overlook the fact that AI tools can-and do-deliver tangible benefits to patients today. VISION is testing a novel individualised care approach designed by clinicians, leveraging latest technology alongside existing diagnostic tests, to facilitate rapid adoption.” commented Concr’s CEO Dr Irina Babina.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!